Toggle navigation
About Us
Company
Management Team
Advisory Board
Investors
Careers
Our Focus
AntiMicrobial Resistance (AMR)
Immunotherapies for Infectious Diseases
Multivalent Immunotherapies for bacterial infections
Science & Technology
The Mechanism
A New Approach
Technology Platform
Pipeline
PNV
UNImAb
SILBA
Partnerships
Industry
R&D
Clinical Trials
Affiliations
Funding
Resources
News
Publications
About Us
Company
Management Team
Advisory Board
Investors
Careers
Our Focus
AntiMicrobial Resistance (AMR)
Immunotherapies for Infectious Diseases
Multivalent Immunotherapies for bacterial infections
Science & Technology
The Mechanism
A New Approach
Technology Platform
Pipeline
PNV
UNImAb
SILBA
Partnerships
Industry
R&D
Clinical Trials
Affiliations
Funding
Resources
News
Publications
News
PRESS RELEASE
Immunethep launches new website and corporate image
27 July 2022
IMTP IN THE NEWS
Immunethep featured in the Top 15 Biotech companies in Portugal
13 July 2022
IMTP IN THE NEWS
PNV in WHO report: multivalent bacterial vaccine candidate
12 July 2022
